BSX's weak solvency and cash conversion raise financing risk
FROM THE WIRE · FINANCE.YAHOO.COM
Boston Scientific's BSX exited the third quarter of 2026 with $609 million in cash and approximately $11.95 billion in total debt, representing gross debt leverage of 1.9 times. Adjusted gross margin contracted 300 basis points year over year to 68%, primarily due to unfavorable…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishShrinking margins and expected 2027 pressure could weigh on the stock of a large medical device maker.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01BSX ended Q3 2026 with $609 million in cash and about $11.95 billion in total debt.
- 02Adjusted gross margin contracted 300 basis points to 68% after the August cybersecurity incident.
- 03The company expects significant gross margin pressure in 2027.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets